Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
SEC Accession No. 0001193125-25-017718
Filing Date
2025-01-31
Accepted
2025-01-31 07:46:00
Documents
2

Document Format Files

Seq Description Document Type Size
1 SC 14D9/A d917985dsc14d9a.htm SC 14D9/A 15779
2 EX-99.(A)(5)(E) d917985dex99a5e.htm EX-99.(A)(5)(E) 19660
  Complete submission text file 0001193125-25-017718.txt   37153
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filed by) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Subject) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 14D9/A | Act: 34 | File No.: 005-88023 | Film No.: 25575944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)